Innovative trial aims to induce remission of type 2 diabetes

December 15, 2015

London, Ontario - Remission is well-known as the goal in cancer treatment but scientists are discovering it's also an exciting possibility for those with type 2 diabetes.

This new concept is being tested by researchers at Lawson Health Research Institute, who are challenging traditional type 2 diabetes treatment and testing an aggressive approach in recently diagnosed patients.

St. Joseph's Hospital in London is one of seven Canadian sites taking part in the innovative trial considered a significant and innovative departure in strategy in the care of people with type 2 diabetes. Known as the REMIT Study, it is being led by the Population Health Research Institute (PHRI), a joint institute of McMaster University and Hamilton Health Sciences. This trial follows a PHRI pilot study of early aggressive treatment that resulted in up to 40 per cent of 83 patients with type 2 diabetes going into remission and not needing any diabetes treatment for at least three months.

"For type 2 diabetes we have a wide array of new drugs, a wide array of new insulins, lots of choices, and we are doing our best with our family doctor colleagues, but we're not winning," explains Lawson researcher and endocrinologist Dr. Irene Hramiak, Chief of the Centre for Diabetes, Endocrinology and Metabolism at St. Joseph's. "We still have 50 per cent of patients with type 2 diabetes who are not reaching their blood sugar targets. Unfortunately our patients still are suffering the complications - amputations, eye disease, dialysis and heart attacks from their diabetes. So we have to stop and ask maybe it's our approach."

The standard treatment for people diagnosed with type 2 diabetes is to start on a single medication, which is then followed by the addition of more drugs and insulin as the disease progresses.

"We don't start multiple drugs all at once," says Dr. Hramiak. "We take one at time. We wait until you run out of efficacy from that drug, which can take a variable length of time and then we add a drug. But over the course of many years, there are lag periods and people spend a lot of time poorly controlled rather than well controlled because of the progressive nature of the disease."

The experimental treatment will see patients receiving intensive treatment - two drugs plus insulin at bedtime - for three months to see if remission can be induced.

"It's a proactive approach," says Dr. Hramiak. "The theory is that we should be aggressive with treatment early in the disease and that may slow the progression of the disease."

A total of 152 patients are being sought in Canada - 25 at St Joseph's Health Care London - who have been diagnosed with type 2 diabetes within the last eight years. Those who would like more information about the trial can call 519 646-6100 ext. 65423.

"It's quite innovative," says Dr. Hramiak of the experimental treatment. "It's really changing the disease and inducing remission rather than treating disease. It's a huge difference to our overall approach."
-end-
For more information:

Dahlia Reich, Communication & Public Affairs
St. Joseph's Health Care London
(519) 646-6100 ext. 65294, pager 10117
dahlia.reich@sjhc.london.on.ca
sjhc.london.on.ca

Laura Goncalves, Communications & External Relations
Lawson Health Research Institute
519-685-8500 ext. 64059, 226-448-1525
laura.goncalves@lawsonresearch.com
lawsonresearch.com

About Lawson Health Research Institute

As the research institute of London Health Sciences Centre and St. Joseph's Health Care, London, and working in partnership with Western University, Lawson Health Research Institute is committed to furthering scientific knowledge to advance health care around the world. http://www.lawsonresearch.com

About St. Joseph's Health Care London

Renowned for compassionate care, St. Joseph's Health Care London is a leading academic health care centre in Canada dedicated to helping people live to their fullest by minimizing the effects of injury, disease and disability through excellence in care, teaching and research. Through partnership with Lawson Health Research Institute and our collaborative engagement with other health care and academic partners, St. Joseph's has become an international leader in the areas of: chronic disease management; medical imaging; specialized mental health care; rehabilitation and specialized geriatrics; and surgery. St. Joseph's operates through a wide range of hospital, clinic and long-term and community-based settings, including: St. Joseph's Hospital; Parkwood Hospital; Mount Hope Centre for Long Term Care; Regional Mental Health Care London; and the Southwest Centre for Forensic Mental Health Care. For more information, visit http://www.sjhc.london.on.ca

Lawson Health Research Institute

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.